Latest news

• Amgen, Servier heart failure drug clears trial hurdle

  than Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine), which were both approved for heart failure in 2015.

• Amgen agrees to take Cytokinetics' heart failure drug into phase III

  It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart

• FDA clears Amgen's Corlaner for heart failure

  Corlaner's approval is based on the results of the phase III SHIFT trial, which compared Corlanor to placebo, in addition to standard of care, in more than 6500 patients. ... Corlanor is thought to work by decreasing heart rate and represents the first